Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease

Huntington's disease (HD) is an inherited progressive neurological disorder for which there is no effective therapy. It is caused by a CAG/polyglutamine repeat expansion that leads to abnormal protein aggregation and deposition in the brain. Several compounds have been shown to disrupt the aggregati...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Emma Hockly, Jamie Tse, Amy L. Barker, Donna L. Moolman, Jean-Luc Beunard, Adrian P. Revington, Kim Holt, Sunny Sunshine, Hilary Moffitt, Kirupa Sathasivam, Benjamin Woodman, Erich E. Wanker, Philip A.S. Lowden, Gillian P. Bates
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Elsevier 2006-01-01
سلاسل:	Neurobiology of Disease
الموضوعات:	Huntington's disease Polyglutamine Neurodegeneration Aggregation Inhibitor Benzothiazole Riluzole
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S0969996105002056
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!